Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia.
Faculty of Science, University of Tabuk, Tabuk 71491, Kingdom of Saudi Arabia.
J Infect Public Health. 2023 Mar;16(3):320-331. doi: 10.1016/j.jiph.2022.12.022. Epub 2022 Dec 31.
There is paucity of data describing the impact of COVID-19 pandemic on antimicrobial resistance. This review evaluated the changes in the rate of multidrug resistant gram negative and gram positive bacteria during the COVID-19 pandemic.
A search was conducted in PubMed, Science Direct, and Google Scholar databases to identify eligible studies. Studies that reported the impact of COVID-19 pandemic on carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta-lactamase inhibitor (ESBL)-producing Enterobacteriaceae, vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Pseudomonas aeruginosa (CPE) were selected. Studies published in English language from the start of COVID-19 pandemic to July 2022 were considered for inclusion.
Thirty eligible studies were selected and most of them were from Italy (n = 8), Turkey (n = 3) and Brazil (n = 3). The results indicated changes in the rate of multidrug resistant bacteria, and the changes varied between the studies. Most studies (54.5%) reported increase in MRSA infection/colonization during the pandemic, and the increase ranged from 4.6 to 170.6%. Five studies (55.6%) reported a 6.8-65.1% increase in VRE infection/colonization during the pandemic. A 2.4-58.2% decrease in ESBL E. coli and a 1.8-13.3% reduction in ESBL Klebsiella pneumoniae was observed during the pandemic. For CRAB, most studies (58.3%) reported 1.5-621.6% increase in infection/colonization during the pandemic. Overall, studies showed increase in the rate of CRE infection/colonization during the pandemic. There was a reduction in carbapenem-resistant E. coli during COVID-19 pandemic, and an increase in carbapenem-resistant K. pneumoniae. Most studies (55.6%) showed 10.4 - 40.9% reduction in the rate of CRPA infection during the pandemic.
There is an increase in the rate of multidrug resistant gram positive and gram negative bacteria during the COVID-19 pandemic. However, the rate of ESBL-producing Enterobacteriaceae and CRPA has decrease during the pandemic. Both infection prevention and control strategies and antimicrobial stewardship should be strengthen to address the increasing rate of multidrug resistant gram positive and gram negative bacteria.
关于 COVID-19 大流行对抗菌药物耐药性影响的数据很少。本综述评估了 COVID-19 大流行期间耐多药革兰阴性和革兰阳性菌的发生率变化。
在 PubMed、Science Direct 和 Google Scholar 数据库中进行检索,以确定符合条件的研究。选择报告 COVID-19 大流行对耐碳青霉烯鲍曼不动杆菌(CRAB)、耐碳青霉烯肠杆菌科(CRE)、产超广谱β-内酰胺酶肠杆菌科(ESBL-PE)、万古霉素耐药肠球菌(VRE)、耐甲氧西林金黄色葡萄球菌(MRSA)和耐碳青霉烯铜绿假单胞菌(CPE)影响的研究。纳入从 COVID-19 大流行开始到 2022 年 7 月发表的英语研究。
选择了 30 项符合条件的研究,其中大多数来自意大利(n=8)、土耳其(n=3)和巴西(n=3)。结果表明,耐药菌的发生率发生了变化,不同研究之间的变化也不同。大多数研究(54.5%)报告大流行期间 MRSA 感染/定植增加,增加幅度为 4.6-170.6%。5 项研究(55.6%)报告大流行期间 VRE 感染/定植增加 6.8-65.1%。大流行期间大肠埃希菌 ESBL 减少 2.4-58.2%,肺炎克雷伯菌 ESBL 减少 1.8-13.3%。对于 CRAB,大多数研究(58.3%)报告大流行期间感染/定植增加 1.5-621.6%。总体而言,研究显示大流行期间 CRE 感染/定植率增加。大流行期间,耐碳青霉烯类大肠埃希菌减少,耐碳青霉烯类肺炎克雷伯菌增加。大多数研究(55.6%)显示大流行期间耐碳青霉烯类铜绿假单胞菌感染率降低 10.4-40.9%。
COVID-19 大流行期间,耐多药革兰阳性和革兰阴性菌的发生率增加。然而,大流行期间产 ESBL 肠杆菌科和 CRPA 的发生率有所下降。应加强感染预防和控制策略以及抗菌药物管理,以解决耐多药革兰阳性和革兰阴性菌的发生率不断上升的问题。